Wei Peng Yong
Overview
Explore the profile of Wei Peng Yong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
3480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Choo J, Kua L, Soe M, Asuncion B, Tan B, Teo C, et al.
Gastric Cancer
. 2023 Feb;
26(3):393-404.
PMID: 36781556
Background: We evaluated the relevance of PD-1CD8 T-cells in gastric cancer (GC) including prognostic significance, association with chemotherapy and immunotherapy sensitivity and correlations with the tumor microenvironment (TME). Methods: Discovery...
12.
Zhang V, Ramachandran G, Loo E, Soh A, Yong W, Siah K
Neurogastroenterol Motil
. 2023 Feb;
35(7):e14536.
PMID: 36780514
Background: Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disease characterized by intermittent abdominal pain with altered bowel habits. Due to the condition's chronicity, patients suffer from poor quality of...
13.
Yong W, Teo F, Teo L, Ng M, Tan T, Low S, et al.
Expert Opin Drug Metab Toxicol
. 2023 Jan;
18(12):805-815.
PMID: 36636012
Introduction: Interstitial lung disease (ILD) or pneumonitis remains an important adverse event identified with treatment with antibody-drug conjugates (ADCs). Drug-induced ILD (DILD) accounts for 3%-5% of common ILD cases and...
14.
Chia D, Sundar R, Kim G, Ang J, Shabbir A, So J, et al.
Ann Surg Oncol
. 2022 Dec;
30(3):1889-1890.
PMID: 36564654
No abstract available.
15.
Low J, Huang Y, Sooi K, Chan Z, Yong W, Lee S, et al.
Front Oncol
. 2022 Dec;
12:932212.
PMID: 36465401
The rising cost of oncological drugs poses a global challenge to patients, insurers, and policy makers, with the leading drugs worldwide by revenue from immune checkpoint inhibitors (ICIs). Despite its...
16.
Yoshino T, Andre T, Kim T, Yong W, Shiu K, Jensen B, et al.
Cancer Sci
. 2022 Nov;
114(3):1026-1036.
PMID: 36369901
The phase 3 KEYNOTE-177 study evaluated pembrolizumab versus chemotherapy with or without bevacizumab or cetuximab in patients with newly diagnosed, microsatellite-instability-high (MSI-H)/mismatch-repair-deficient (dMMR) metastatic colorectal cancer (mCRC). Primary endpoints were...
17.
Myint K, Chuang L, Teh Y, Mawan N, Shi E, Mok M, et al.
iScience
. 2022 Oct;
25(10):105194.
PMID: 36217548
We reported earlier that IQGAP3 is an important stem cell factor in rapidly proliferating isthmus stem cells in the stomach and that IQGAP3 expression is robustly induced in terminally differentiated...
18.
Chia D, Ang J, Sundar R, Kim G, Shabbir A, So J, et al.
Ann Surg Oncol
. 2022 Oct;
29(13):8606-8607.
PMID: 36192514
No abstract available.
19.
Yau T, Tai D, Chan S, Huang Y, Choo S, Hsu C, et al.
Liver Cancer
. 2022 Sep;
11(5):426-439.
PMID: 36158587
Background: Asia has a high burden of hepatocellular carcinoma (HCC) due to the high rates of chronic hepatitis B infection and accounts for 70% of HCC cases globally. In the...
20.
Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, et al.
Ann Surg Oncol
. 2022 Sep;
29(13):8597-8605.
PMID: 36070113
Background: Adding intraperitoneal paclitaxel (IP-PTX) to paclitaxel/5-fluoropyrimidine has shown promising results in patients with gastric cancer peritoneal metastases (GCPM) but has not been studied with standard-of-care platinum/fluoropyrimidine combinations. Our goal...